A GP guide to pre-eclampsia screening
Need to know: Pre-eclampsia is a multisystem disorder that typically affects 2-5% of pregnant women and is one of the leading global causes of maternal…
Tag: Renal medicine
A GP guide to managing gout
Gout is one of the most common inflammatory joint diseases and presents a significant burden for many people in Australia. There are several gaps between…
‘Shrunken pore syndrome’ flags mortality risk in T2DM: Aussie study
A low ratio of cystatin C–based eGFR to creatinine-based eGFR in people with type 2 diabetes is linked to mortality regardless of conventional markers of…
Dr John Dique: the ‘uncompromising racist’ who made Australia’s first dialysis machine
MECHANICAL KIDNEY IS A BOON IN ACCIDENTS That was the 1954 headline in the newspaper Truth that announced the start of dialysis in Australia. This…
Solving a weightlifter’s renal riddle in a case of misdiagnosed CKD
Simon, aged 56, takes pride in his good health. He works long hours as a bank manager, but also prioritises maintaining a healthy lifestyle and…
SGLT-2 inhibitors stave off type 2 diabetes in HF, studies show
New analyses of trial data suggest SGLT-2 inhibitors reduce incident diabetes in patients with cardiovascular or kidney disease, a team of international researchers says. Dapagliflozin…
Doctors say they may be forced to choose who lives or dies in dialysis crisis
A group of renal specialists say they being forced to ration dialysis through shorter or reduced sessions as services struggle to meet demand. Dozens of…
Oddly puffy shins and frothy urine
Daniel is a 19-year-old university student who presents to his GP with a one-month history of bilateral pitting oedema to his mid-shins and three months…
Semaglutide should be first-line option for diabetic CKD, doctors say
Semaglutide should be a first-line treatment option for adults with diabetic chronic kidney disease and albuminuria, say renal specialists. It follows a landmark Australian-led trial,…
Renal cell carcinoma: Survival benefit with pembrolizumab extends to four years
Patients given pembrolizumab for renal cell carcinoma continue to reap the benefits at four years’ follow-up, with researchers reporting a 38% lower risk of death…
